Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Universidade De Santiago De Compostela

Verified siteinfo

Spain Calle Choupana Da S/n, 15706 Santiago De Compostela, Spain

  • 209 trials recruiting
  • Non-small cell lung cancer · Plasma cell myeloma · Dermatitis atopic
  • Adults and children

About Specializations

Universidade De Santiago De Compostela in Santiago De Compostela, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Plasma cell myeloma, Dermatitis atopic, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms and Blood Cancer Research

At Universidade De Santiago De Compostela, clinical research is focused on neoplasms, with a strong emphasis on hematology and cancers affecting the blood and lymphatic system. The studies are centered on treatment-naïve mantle cell lymphoma, exploring new approaches to improve outcomes for people newly diagnosed with this rare cancer.

  • Evaluating new treatment combinations for mantle cell lymphoma
  • Assessing how effectively therapies can produce deep remission in hematologic malignancies
  • Supporting better disease control for patients with newly diagnosed lymphoma

The research at this educational institution in Santiago De Compostela is aimed at testing whether modern treatment strategies can improve remission rates and strengthen care for patients with lymphoma.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Calle Choupana Da S/n15706 Santiago De CompostelaSpain
Open in maps ↗
Recruiting now
209 trials
Conditions studied
302
Partner status
Verified site

More sites in Santiago De CompostelaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

603 clinical trials

Papulopustular rosacea

Recruiting

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Recruiting

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Amyotrophic lateral sclerosis

Recruiting

A study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Ferrer Internacional S.A.

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

COVID-19

Recruiting

A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Molnupiravir
  • Sponsor:Merck Sharp & Dohme LLC

Pancreatic neuroendocrine tumour

Recruiting

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

Palmoplantar pustulosis

Recruiting

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Ischaemic stroke

Recruiting

A Study to Test if Rinvecalinase Alfa is Safe and Works for Treating Acute Ischemic Stroke in Patients with Moderate Stroke Severity

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Diamedica Therapeutics Inc.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.